ArticleScientific reports2015
Targeted gold-coated iron oxide nanoparticles for CD163 detection in atherosclerosis by MRI.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 75 citations in OpenAlex.
- Applications of Bioinorganic Nano-Based Delivery Systems-Diagnostics and Therapeutics.Drug development research · 2026Review
- Targeted radio-thermo dual sensitizer magnetic gold core-shells nanoparticles enhance radioresistant glioblastoma via promoting apoptosis and ROS generation.Cancer cell international · 2026Article
- Gold Nanoparticles in Atherosclerosis: A Dual Approach to Diagnosis and Therapy.Molecular imaging and biology · 2025Review
- Emerging Trends and Innovations in the Treatment and Diagnosis of Atherosclerosis and Cardiovascular Disease: A Comprehensive Review towards Healthier Aging.Pharmaceutics · 2024Review
- Nanotechnology-based non-viral vectors for gene delivery in cardiovascular diseases.Frontiers in bioengineering and biotechnology · 2024Review
- Molecular imaging nanoprobes and their applications in atherosclerosis diagnosis.Theranostics · 2024Review
- In silico based analysis to explore genetic linkage between atherosclerosis and its potential risk factors.Biochemistry and biophysics reports · 2023Article
- Biomimetic nanomedicines for precise atherosclerosis theranostics.Acta pharmaceutica Sinica. B · 2023Review
- Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Review
- Antitumor effects of targeted killing of tumor-associated macrophages under photothermal conditions.Lasers in medical science · 2022Article
- Latest advances in biomimetic nanomaterials for diagnosis and treatment of cardiovascular disease.Frontiers in cardiovascular medicine · 2022Review
- Gold Nanoparticle-Based Therapy for Muscle Inflammation and Oxidative Stress.Journal of inflammation research · 2022Review
- Advanced targeted nanomedicines for vulnerable atherosclerosis plaque imaging and their potential clinical implications.Frontiers in pharmacology · 2022Review
- Nanotechnological approach to delivering nutraceuticals as promising drug candidates for the treatment of atherosclerosis.Drug delivery · 2021Review
- Iron Oxide Nanoparticles in Regenerative Medicine and Tissue Engineering.Nanomaterials (Basel, Switzerland) · 2021Review
- Pharmacokinetics of Single Domain Antibodies and Conjugated Nanoparticles Using a Hybrid near Infrared Method.International journal of molecular sciences · 2021Article
- Nanoparticle theranostics in cardiovascular inflammation.Seminars in immunology · 2021Review
- Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis.Advanced drug delivery reviews · 2021Review
- Molecular and Nonmolecular Imaging of Macrophages in Atherosclerosis.Frontiers in cardiovascular medicine · 2021Review
- Nanotechnology for Targeted Therapy of Atherosclerosis.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD163 is a membrane receptor expressed by macrophage lineage. Studies performed in atherosclerosis have shown that CD163 expression is increased at inflammatory sites, pointing at the presence of intraplaque hemorrhagic sites or asymptomatic plaques. Hence, imaging of CD163 expressing macrophages is an interesting strategy in order to detect atherosclerotic plaques. We have prepared a targeted probe based on gold-coated iron oxide nanoparticles vectorized with an anti-CD163 antibody for the specific detection of CD163 by MRI. Firstly, the specificity of the targeted probe was validated in vitro by incubation of the probe with CD163(+) or (-) macrophages. The probe was able to selectively detect CD163(+) macrophages both in human and murine cells. Subsequently, the targeted probe was injected in 16 weeks old apoE deficient mice developing atherosclerotic lesions and the pararenal abdominal aorta was imaged by MRI. The accumulation of probe in the site of interest increased over time and the signal intensity decreased significantly 48 hours after the injection. Hence, we have developed a highly sensitive targeted probe capable of detecting CD163-expressing macrophages that could provide useful information about the state of the atheromatous lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.